MX2024004216A - Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb. - Google Patents

Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb.

Info

Publication number
MX2024004216A
MX2024004216A MX2024004216A MX2024004216A MX2024004216A MX 2024004216 A MX2024004216 A MX 2024004216A MX 2024004216 A MX2024004216 A MX 2024004216A MX 2024004216 A MX2024004216 A MX 2024004216A MX 2024004216 A MX2024004216 A MX 2024004216A
Authority
MX
Mexico
Prior art keywords
inhibitors
kras
combination therapies
erbb family
pan erbb
Prior art date
Application number
MX2024004216A
Other languages
English (en)
Spanish (es)
Inventor
James Gail Christensen
Peter Olson
Jill Hallin
Vickie Bowcut
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of MX2024004216A publication Critical patent/MX2024004216A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2024004216A 2021-10-05 2022-10-04 Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb. MX2024004216A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163252534P 2021-10-05 2021-10-05
PCT/US2022/045621 WO2023059596A1 (en) 2021-10-05 2022-10-04 COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH Pan ErbB FAMILY INHIBITORS

Publications (1)

Publication Number Publication Date
MX2024004216A true MX2024004216A (es) 2024-06-20

Family

ID=85803674

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004216A MX2024004216A (es) 2021-10-05 2022-10-04 Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb.

Country Status (10)

Country Link
US (1) US20240408099A1 (enExample)
EP (1) EP4412717A4 (enExample)
JP (1) JP2024537136A (enExample)
KR (1) KR20240089340A (enExample)
CN (1) CN118369119A (enExample)
AU (1) AU2022359880A1 (enExample)
CA (1) CA3233567A1 (enExample)
IL (1) IL311835A (enExample)
MX (1) MX2024004216A (enExample)
WO (1) WO2023059596A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4436571A4 (en) * 2021-11-24 2025-10-15 Merck Sharp & Dohme Llc SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS
AU2024321817A1 (en) * 2023-08-08 2026-03-05 Quanta Therapeutics, Inc. Combination therapies with kras modulators
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2026060400A1 (en) * 2024-09-16 2026-03-19 Quanta Therapeutics, Inc. Combination therapies with kras modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013139423A1 (en) 2012-03-19 2013-09-26 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
EA202190749A1 (ru) * 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
TW202317589A (zh) * 2021-07-14 2023-05-01 美商尼坎醫療公司 作為kras抑制劑的伸烷基衍生物

Also Published As

Publication number Publication date
JP2024537136A (ja) 2024-10-10
AU2022359880A1 (en) 2024-04-11
CA3233567A1 (en) 2023-04-13
KR20240089340A (ko) 2024-06-20
IL311835A (en) 2024-05-01
WO2023059596A1 (en) 2023-04-13
EP4412717A4 (en) 2025-08-13
CN118369119A (zh) 2024-07-19
EP4412717A1 (en) 2024-08-14
US20240408099A1 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
MX2024004216A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb.
MX2021002804A (es) Terapias de combinacion.
MX2024008551A (es) Terapias de combinacion.
MX2024004215A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de sos1.
MX2025011553A (es) Composiciones para inducir la hidrolisis de ras gtp y sus usos
CO2026004964A2 (es) Moduladores de kras
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
CL2021002966A1 (es) Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer.
CL2023003965A1 (es) Inhibidores cdk2.
BR112022026186A2 (pt) Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras
CL2025002554A1 (es) Compuestos tricíclicos inhibidores de parp1 y uso para tratar cáncer.
CL2023002223A1 (es) Inhibidores de cdk2 y métodos de uso de los mismos
CO2025005378A2 (es) Compuestos n-(5-sustituido-[(1,3,4-tiadiazolil) o (1,3-tiazolil)](sustituido)carboxamida, composiciones farmacéuticas y métodos de preparación de los compuestos amida y de su uso
CL2022003511A1 (es) Inhibidores de alk2 para el tratamiento de la anemia.
MX2024004213A (es) Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados.
EA202190776A1 (ru) Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами
CO2020013834A2 (es) Ciertos compuestos de pladienolida y métodos de uso
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
CO2022000266A2 (es) Inhibidores de enzimas
MX2022006500A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
CL2025002366A1 (es) Compuesto que contiene trifluorometilsulfonilo.
BR112022007616A2 (pt) Métodos e composições para tratar doença falciforme com um inibidor de ferroportina (vit-2763)
CL2023002446A1 (es) Inhibidores de enzimas
MX2024003989A (es) Metodos de tratamiento del cancer y composiciones farmaceuticas de los mismos.